Autophagy and Cancer 2022

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Cell Biology and Tissue Engineering".

Deadline for manuscript submissions: closed (1 May 2022) | Viewed by 4073

Special Issue Editors


E-Mail Website
Guest Editor
Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Interests: oncology; medicine; cancer biology; autophagy; molecular science
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Molecular Oncology Unit, Department of Biological Chemistry, National and Kapodistrian University of Athens, Athens, Greece
Interests: Molecular Oncology Unit, Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Autophagy, as a basic homeostatic and catabolic process, is responsible for the degradation and recycling of proteins and cellular components. The mechanism of autophagy has a crucial role in several cellular functions and its dysregulation is associated with tumorigenesis, tumor–stroma interactions, and resistance to cancer therapy. A plethora of studies associate autophagy as a key regulator of the tumor microenvironment and cellular immune response in different types of cancer. It has been proven that autophagy affects the microenvironment of the tumor and vice versa. Cancer cells coexist with their microenvironment, and the role of autophagy in modulating their interactions with other cell types may be a target for the modulation of autophagy, as a potential anti-cancerous treatment. Autophagy is also a key factor in the function of APCs and T-cells. Autophagy is implicated in the presentation of antigens in both MHC-I and MHC-II in dendritic cells (DCs). Finally, autophagy contributes to the functional activity of immune cells by creating T-cell memory, depending on autophagy. Increased levels of autophagy characterize the cross-presentation capability of DCs compared with DCs that do not cross-present antigens, and the autoimmune inhibition that reduces the cross-presentation of MHC-I-mediated MHC-I. This Special Issue will aim to understand and illuminate the role of autophagy in the tumor microenvironment in order to strengthen the response of the immune system and overcome anti-tumor immune resistance in immunotherapy.

In this special issue, the scope includes:

  1. The role of autophagy in tumor microenvironment;
  2. The role of autophagy as regulator of immune responses;
  3. Immune-related signaling molecules that regulate autophagy;
  4. The effect of autophagy on modulate immune system components, mainly containing natural killer (NK) cells, macrophages, dendritic cells (DCs), and T and B lymphocytes;
  5. How autophagy enhances or attenuates the effect of immunotherapy;
  6. How to regulate autophagy to strengthen innate and adaptive immune responses and overcome anti-tumor immune resistance in immunotherapy for tumors.

Dr. Evangelos Koustas
Dr. Panagiotis Sarantis
Guest Editors

Keywords

  • autophagy
  • immunotherapy
  • checkpoint inhibitors
  • tumor microenvironment
  • immune system components
  • anti-tumor immune resistance

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 1089 KiB  
Review
Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells
by Chenmala Karthika, Raman Sureshkumar, Mehrukh Zehravi, Rokeya Akter, Faraat Ali, Sarker Ramproshad, Banani Mondal, Milton Kumar Kundu, Abhijit Dey, Md. Habibur Rahman, Angela Antonescu and Simona Cavalu
Life 2022, 12(6), 811; https://doi.org/10.3390/life12060811 - 30 May 2022
Cited by 16 | Viewed by 2938
Abstract
Even though various treatment methods are available for cancer, the death curve is not reducing. The diagnosis of cancer at the fourth stage and drug resistance are the leading reasons for treatment failure and lower survival rates. In this review article, we summarize [...] Read more.
Even though various treatment methods are available for cancer, the death curve is not reducing. The diagnosis of cancer at the fourth stage and drug resistance are the leading reasons for treatment failure and lower survival rates. In this review article, we summarize the possible pitfalls during cancer treatment in general, which mainly include multidrug resistance, and propose a hypothesis for colorectal cancer specifically. We also evaluate multidrug resistance in cancer in general and colorectal cancer in particular and hypothesize a concept based on combination therapy with 5-fluorouracil, curcumin, and lipids for the possible management of colorectal cancer. In addition, a hypothetical approach, combining a synthetic agent and a natural chemotherapeutic agent, to treating colorectal cancer is also discussed. This hypothesis could improve the management of colorectal cancer. Full article
(This article belongs to the Special Issue Autophagy and Cancer 2022)
Show Figures

Figure 1

Back to TopTop